IsoRay adds Proxcelan sites

Therapeutic radiopharmaceutical developer IsoRay Medical reported that the University of Pittsburgh Medical Center (UPMC) in Pittsburgh, and Arizona Oncology Services (AOS) of Phoenix are two of the latest medical facilities offering prostate cancer patients the company’s Proxcelan brachytherapy seeds, a proprietary cesium-131 formulation.


Proxcelan has U.S. Food and Drug Administration 510(k) clearance for treating prostate cancer and other malignancies.

The UPMC facility encompasses 19 hospitals and 40 cancer centers with 75 affiliated oncologists and AOS serves more than 4,000 patients annually, according to the Richland, Wash.-based IsoRay.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup